START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia , including utilization and patient satisfaction



AUSTEDO is the... | June 10, 2023

Related Keywords

United States , American , Andrew Cutler , Eric Hughes , Drug Administration , Teva Pharmaceuticals , Teva Neuroscience Inc , Psych Congress Elevate , Subcutaneous Administration Olanzapine For , Neuroscience Education Institute , Mental Health Services Administration , National Alliance On Mental Illness , Teva Pharmaceutical Industries Ltd , National Pregnancy Registry For Atypical Antipsychotics , Teva Pharmaceutical Industries , Executive Vice President , Chief Medical Officer , Clinical Global Impression , Patient Global Impression , Associate Clinical Professor , Medical University , Neuroscience Education , Sample Titration Kit , Poster Presentations , Real World Effectiveness , Deutetrabenazine When Initiated Using , Week Patient Titration Kit , Interim Results , Patient Satisfaction With , Patient Titration Kit , Population Estimate , Patients With Tardive Dyskinesia , Real World Clinical Practice , Across Age Groups , Underlying Psychiatric Conditions , Payer Types , Healthcare Professional Perspectives , Key Impacts , Tardive Dyskinesia , Long Acting Subcutaneous Antipsychotic , Local Tolerability , Injection Site Reactions , Long Term Safety , Patients With Schizophrenia , Double Blind Study , Placebo Controlled Trial Assessing Safety , Subcutaneous Administration , Extended Release Injectable Suspension Use , Adults With Schizophrenia , Patient Characteristics , Transitioning Patients , Long Acting Injectable Antipsychotics , Hypothetical Case , Initiating Long Acting Injectable Antipsychotics , Release Tablets , Adverse Events , Malignant Syndrome , Melanin Containing Tissues , Adverse Reactions , Prescribing Information , Motor Impairment , National Pregnancy Registry , Atypical Antipsychotics , Hepatic Impairment , Pharmaceutical Industries , Private Securities Litigation Reform Act , Quarterly Report , Annual Report , Term Deutetrabenazine Treatment , Sustained Benefits , Open Label Extension , Huntington Disease , Nova Science , From Phenomenology , Mental Illness , Mental Health Services , Current Prescribing ,